Medtronic announces cash dividend for third quarter of fiscal year 2025
Werte in diesem Artikel
GALWAY, Ireland, Dec. 5, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025, to shareholders of record at the close of business on December 27, 2024.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts: | |
Erika Winkels | Ryan Weispfenning |
Public Relations | Investor Relations |
+1-763-526-8478 | +1-763-505-4626 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-cash-dividend-for-third-quarter-of-fiscal-year-2025-302324330.html
SOURCE Medtronic plc
Ausgewählte Hebelprodukte auf Medtronic
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Medtronic
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Medtronic PLC
Analysen zu Medtronic PLC
Datum | Rating | Analyst | |
---|---|---|---|
04.02.2019 | Medtronic Strong Buy | Needham & Company, LLC | |
03.01.2019 | Medtronic Buy | Deutsche Bank AG | |
16.10.2018 | Medtronic Overweight | Barclays Capital | |
22.08.2018 | Medtronic Hold | Stifel, Nicolaus & Co., Inc. | |
13.08.2018 | Medtronic Strong Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
04.02.2019 | Medtronic Strong Buy | Needham & Company, LLC | |
03.01.2019 | Medtronic Buy | Deutsche Bank AG | |
16.10.2018 | Medtronic Overweight | Barclays Capital | |
22.08.2018 | Medtronic Hold | Stifel, Nicolaus & Co., Inc. | |
13.08.2018 | Medtronic Strong Buy | Needham & Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
01.06.2016 | Medtronic Neutral | Wedbush Morgan Securities Inc. | |
23.11.2012 | Medtronic hold | Deutsche Bank Securities | |
22.11.2012 | Medtronic neutral | Credit Suisse Group | |
22.11.2012 | Medtronic neutral | JP Morgan Chase & Co. | |
21.11.2012 | Medtronic sector perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
22.08.2007 | Medtronic underweight | Morgan Stanley | |
29.09.2006 | Update Kyphon Inc.: Underweight | Morgan Stanley |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Medtronic PLC nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen